Pharsight

Exem Foam Kit patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9034300 GISKIT Composition and method for medical imaging of body cavities
Oct, 2030

(6 years from now)

US9259494 GISKIT Composition and method for medical imaging of body cavities
May, 2035

(10 years from now)

US9849199 GISKIT Composition and method for medical imaging of body cavities
Feb, 2036

(11 years from now)

Exem Foam Kit is owned by Giskit.

Exem Foam Kit contains Air Polymer-Type A.

Exem Foam Kit has a total of 3 drug patents out of which 0 drug patents have expired.

Exem Foam Kit was authorised for market use on 07 November, 2019.

Exem Foam Kit is available in foam;intrauterine dosage forms.

Exem Foam Kit can be used as use in sonohysterosalpinography to assess fallopian tube patency.

Drug patent challenges can be filed against Exem Foam Kit from 08 November, 2023.

The generics of Exem Foam Kit are possible to be released after 11 February, 2036.

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Nov 07, 2024

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

Drugs and Companies using AIR POLYMER-TYPE A ingredient

NCE-1 date: 08 November, 2023

Market Authorisation Date: 07 November, 2019

Treatment: Use in sonohysterosalpinography to assess fallopian tube patency

Dosage: FOAM;INTRAUTERINE

More Information on Dosage

EXEM FOAM KIT family patents

Family Patents